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Background and Objective: Results
of hematopoietic stem cell transplantation
(HSCT) in childhood acute leukemias,
are still unsatisfactory, however better
than obtained with conventional
chemotherapy. Probability of long-term
survival after HSCT is still only 40% - 50%.
The main cause of failure remains relapse
of the disease. Current possibilities
to augment an antileukemic effect
of HSCT include: protection of GvHD
and introduction of adoptive immuno-
therapy combined with the results of mo-
lecular chimerism and minimal residual
disease. Another possibility is the use
of more intensive or tailored preparative
regimen (prep-reg) before HSCT and mo-
dulation of drug resistance of residual
leukemic cells against agents used
in prep-reg. The aim of the study
is the analysis of in vitro drug resistance
profile in aspect of leukemia relapse after
HSCT.
Patients and Methods: A total number
of 22 children with acute leukemia
(14 ALL, 8 AML), aged 1,9-17 years, who
underwent HSCT, were included into
the study. For all children, drug resistance
profile was done by the MTT assay.
Leukemic cells of each child were tested
for cytotoxicity of up to 26 drugs (busulfan
and melfalan was not tested). Children
who have died due to peritransplant
complications were excluded from the stu-
dy. In 13 children HSCT was performed
from HLA identical sibling, in 2 from MUD,
in 1 from MMRD and 6 children had
autotransplantation. 8/22 children relapsed
after HSCT. Drug resistance profile was
performed in Laboratory of Clinical and
Experimental Oncology in Bydgoszcz.
The cytotoxicity was expressed
as the concentration of drug, which was
lethal to 50% of tested blasts. Children
with ALL were prepared to HSCT with:
FTBI/vP±CY (6 patients) or BU/vP/CY
(8 patients). Before MUD-HSCT, ATG was
also given. AML children were conditioned
with one the following sets of drugs:
BU/vP/CY, BU/CY/MEL, BU/CY, BU/MEL,
TREONP/CY, TREO/FLU/ATG, TREIFLU/MEL.
Results: Children who relapsed after
HSCT showed higher in vitro resistance
of leukemic blasts to most of tested drugs
including cyclophosphamide (3,3-fold) and
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fludarabine (2,3-fold). Only for 4/26 tested
drugs chemosensitivity of relapsed pa-
tients was better, i.e.: to treosulfan
(4,8-fold), etoposide (1,7-fold), thiotepa
(4,6-fold) and mercaptopurine (1,7-fold)
(all differences did not reach statistical
significance). 5/6 children prepared with
FTBI stays in remission.
Conclusions: The results of this ana-
lysis might suggest that relative sensitivity
of leukemic blasts to treosulfan and eto-
poside is not sufficient to prevent patient
from relapse after HSCT. This study give
an advantage for the use of cyclo-
phosphamide and FTB! in pre-reg,
however this observations require further
investigations.
This work was supported by grant
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We report a 10-year old girl with a dia-
gnosis of myelodysplastic syndrome, who
after first bone marrow transplantation
(HLA -matched sibling donor - May 1999)
suffered from relapse (Dec 2001) and
subsequently was treated by donor
lymphocyte infusions (twice) with no res-
ponse. We decided to perform a second
transplantation from the same donor but
with the use of different conditioning
regimen. It consisted of: treosulfan
(10 g/m2/day for 3 days, fludarabine
(30 mg/kg/day for 5 days) and melphalan
(140 mg/kg/day single dose). On day "0,,
(30 May 2001) she was infused with bone
marrow from her 8-year old, HLA-identical
S23
sister (20 x 106 CD34 cells/kg). As acute
graft versus host disease prophylaxis she
received cyclosporin A (1,5 mg/kg from
day - 1). From day +16 we observed
aGVHD ,,0 in the skin and gastrointestinal
tract. Administration of metylprednisolon
in max. dose of 1,5 mg/kg proved effect-
tive. No toxicity attributable to the con-
ditioning regimen was noted. She was
discharged on day +36.
Complete donor chimerism was reached
by day + 14 and has not changed since
then. On day + 183 the girl is doing well
with stable haematopoiesis of donor origin.
We conclude that preparative regimen
containing treosulfan is a reasonable
option in heavily treated children under-
going bone marrow transplantation.
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Mitochondrial protein bcl-2 is an impor-
tant inhibitor of apoptosis. Blocking
expression of bcl-2 gene by antisense
oligonucleotides (AS-ODN) administration
may result with higher chemosensitivity
of leukemic cells. C-myb is one of the re-
gulatory proteins of cell cycle. Decreasing
its level by antisense oligonucleotides
(AS-ODN) may result with decreased
leukemic cells proliferation.
infusion via central vein catheter at dose
of 0,5-1,2 mg/kg/day. Duration of the tre-
atment was 10 days. We used three
protocols of chemotherapy combined with
antisense infusion. The first protocol was
based on Fludarabine and Cytarabine
(4 patients), the second on Topotecan and
Cyclophosphamide (2 patients). If treat-
ment based on those protocols was not
effective, infusion of AS-ODN with chemo-
therapy based on Paclitaxel and Doxo-
rubicin was introduced (2 patients). G-CSF
was administrated in each case.
No side effects were observed during
AS-ODN administration. The expression
of bcl-2 protein was measured in four
patients (FACS analysis). The decreasing
expression of bcl-2 protein more than
1/3 of the initial value was detected in two
cases. One complete remission has been
achieved lasting 3 months. Two patients
died due to disease's progress.
The preliminary observation showed that
antisense administration is safe and has
no clinically relevant side effects. Higher
dose and repeated AS-ODN infusion
seems to be necessary to achieve better
disease control.
boys/girls age sex dgn relapse Post auto-
PBSeT
Patient A 17 years m ALL-T II 1
Patient B 9 years m ALL-oreB II 1
Patient C 11 years m NHL-LCAL IV 2
Two boys with relapsed ALL after auto
PBSCT and 1 boy with relapsed NHL after
second auto PBSCT were treated with
AS-ODN.
Antisense oligonucleotide anti bcl-2
(18-mer) or anti C-myb was modified
by thioester group supplementation. It was
administrated as a continuous 24-hour
S24
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